
Corcept Therapeutics (CORT) Stock Forecast & Price Target
Corcept Therapeutics (CORT) Analyst Ratings
Bulls say
Corcept Therapeutics has demonstrated a strong financial trajectory, with risk-adjusted sales projections increasing from $171 million in 2026 to peak sales of $1.9 billion by 2031, reflecting significant growth potential within its oncology pipeline. The recent FDA approval of relacorilant following positive survival data from the ROSELLA trial enhances market penetration expectations for ovarian cancer therapies, raising the anticipated market share from 20% to 25%. Additionally, the company plans to bolster its sales efforts with a dedicated team of 50 oncology sales representatives, further supporting operational growth and the potential for expansive revenue generation in the coming years.
Bears say
Corcept Therapeutics has seen a significant downgrade in its 12-month price target, dropping from $105 to $67 per diluted share, primarily due to anticipated pricing pressures on Korlym sales, which may decline due to increased discounts for its generic version and potential regulatory changes. The company's outlook has been further complicated by a Complete Response Letter (CRL) for relacorilant in Cushing's syndrome, leading to a substantial decline in share prices and concerns regarding management turnover that could hinder clinical development progress. Additionally, the increase in the discount rate from 10% to 12% highlights elevated execution risks, further exacerbating the negative financial outlook for the company.
This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Corcept Therapeutics (CORT) Analyst Forecast & Price Prediction
Start investing in Corcept Therapeutics (CORT)
Order type
Buy in
Order amount
Est. shares
0 shares